Evidence map›Paper›PMID 34005836›Full record

ArticleNeurourology and urodynamics2021

Is a 50% improvement threshold adequate to justify progression from sacral neuromodulation testing to implant?

David K Charles, Ross G Everett, Zachary J Prebay, Truman P Landowski, R Corey O'Connor, Michael L Guralnick

Abstract read
PubMed Publisher
In one paragraph

Article in Neurourology and urodynamics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

David K CharlesDepartment of Urologic Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Ross G EverettDepartment of Urologic Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.ORCID 0000-0003-1706-0467
Zachary J PrebayDepartment of Urologic Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.ORCID 0000-0002-9494-9633
Truman P LandowskiDepartment of Urologic Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
R Corey O'ConnorDepartment of Urologic Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.ORCID 0000-0002-2546-9791
Michael L GuralnickDepartment of Urologic Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.ORCID 0000-0001-9869-3076

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeA ≥50% subjective improvement in urinary symptoms during sacral neuromodulation testing (SNM-I) is currently used as the indication for progression to second-stage implantation (SNM-II). While most patients will have successful SNM-I and proceed to SNM-II, deterioration in efficacy over time has been reported. It remains unclear if the durability of efficacy is related to the initial symptom reduction. We sought to determine if the degree of improvement after SNM-I is sufficient to predict long-term success.

methodsThe records of all patients who underwent sacral neuromodulation (SNM) for overactive bladder were reviewed. Subjects were divided into those who reported 50%-75% improvement (Group 1) and more than 75% improvement (Group 2) after SNM-I. Differences in clinical variables and long-term device efficacy were compared between groups.

resultsOf 213 patients who underwent SNM-I, 137 underwent permanent device implantation. A total of 76 (55%) and 61 (45%) patients reported 50%-75% (Group 1) and more than 75% (Group 2) symptomatic improvement, respectively. With a mean follow-up of 46 months, 44% of Group 1 patients and 68% of Group 2 patients still had a functioning device providing the symptomatic benefit (p = 0.007). Univariate analyses identified the presence of stress urinary incontinence at baseline and having a more than 75% improvement after SNM-I as predictors of long-term functional success.

conclusionsCompared to patients reporting 50%-75% symptomatic reduction after SNM-I, individuals with a more than 75% improvement during SNM-I were more likely to maintain device efficacy over time. Additional study is warranted to determine if the improvement threshold for progression to SNM-II should be increased.

Indexed as

Electric Stimulation TherapyUrinary Bladder, OveractiveHumansSacrococcygeal RegionSacrumTreatment Outcomeoveractive bladdersacral neuromodulation

Identifiers

PMID34005836

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.